- Pharmaceutical Products
- Products By Brand Name
- Products By Dosage Form
- Products By Generic Name
- Products By Therapeutic Class
Find a product
Find Generic
Brirel
Ticagrelor
Description:
Ticagrelor, a cyclopentyltriazolopyrimidine which is a reversible platelet aggregation inhibitor.
Ticagrelor, a cyclopentyltriazolopyrimidine which is a reversible platelet aggregation inhibitor.
Indications:
Acute Coronary Syndrome. Ticagrelor is a P2Y z platelet inhibitor indicated to reduce the rate of thrombotic carcliovascular events in patients with Acute Coronary Syndrome (ACS) (unstable angina, non-ST elevation myocardial infarction, or ST elevated myocardial infarction). Ticagrelor has been shown to reduce the rate of cardiovascular death, myocardial infarction or stroke in ACS patients. In patients treated with PCI, it also reduces the rate of stent thrombosis.
Acute Coronary Syndrome. Ticagrelor is a P2Y z platelet inhibitor indicated to reduce the rate of thrombotic carcliovascular events in patients with Acute Coronary Syndrome (ACS) (unstable angina, non-ST elevation myocardial infarction, or ST elevated myocardial infarction). Ticagrelor has been shown to reduce the rate of cardiovascular death, myocardial infarction or stroke in ACS patients. In patients treated with PCI, it also reduces the rate of stent thrombosis.
Mode of Action:
Ticagrelor reversibly bincls with the platelet P2Y12 adenosine diphosphate (ADP) receptor and thereby inhibits signal transduction and platelet aggregation.
Ticagrelor reversibly bincls with the platelet P2Y12 adenosine diphosphate (ADP) receptor and thereby inhibits signal transduction and platelet aggregation.
Other Brands From Same Therapeutic Class
